Metabolism and Brain Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Legler, 1999, Cancer surveillance series: brain and other central nervous system cancers: recent trends in incidence and mortality, J Natl Cancer Inst, 91, 1382, 10.1093/jnci/91.16.1382
Wrensch, 2002, Epidemiology of primary brain tumors: current concepts and review of the literature, Neuro Oncol, 4, 278, 10.1093/neuonc/4.4.278
Furnari, 2007, Malignant astrocytic glioma: genetics, biology, and paths to treatment, Genes Dev, 21, 2683, 10.1101/gad.1596707
Loius, 2007, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, 114, 97, 10.1007/s00401-007-0243-4
Tran, 2010, Survival comparison between glioblastoma multiforme and other incurable cancers, J Clin Neurosci, 17, 417, 10.1016/j.jocn.2009.09.004
Bauchet, 2010, Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004, Neuro-oncol, 12, 725, 10.1093/neuonc/noq030
Schneider, 2010, Gliomas in adults, Dtsch Arztebl Int., 107, 799
Walker, 1978, Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas, A cooperative trial. J Neurosurg, 49, 333
Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330
Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382
Parsons, 2011, The genetic landscape of the childhood cancer medulloblastoma, Science, 331, 435, 10.1126/science.1198056
Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 61, 759, 10.1016/0092-8674(90)90186-I
2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385
Barbosa, 2008, Association of EGFR c.2073A>T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case–control study, Int J Biol Markers, 23, 140, 10.1177/172460080802300302
Burim, 2009, ICAM-1 (Lys469Glu) and PECAM-1 (Leu125Val) polymorphisms in diffuse astrocytomas, Clin Exp Med, 9, 157, 10.1007/s10238-009-0040-6
Lino, 2009, Translating biology into clinics: the case of glioblastoma, Curr Opin Cell Biol, 21, 311, 10.1016/j.ceb.2008.12.009
Larsen, 2010, Genetic and molecular abnormalities of glioblastomas (GBM), Bull Cancer, 97, 1389, 10.1684/bdc.2010.1215
Gerson, 2004, MGMT: its role in cancer aetiology and cancer therapeutics, Nature Rev Cancer, 4, 296, 10.1038/nrc1319
Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331
Weller, 2010, MGMT promoter methylation in malignant gliomas: ready for personalized medicine?, Nat Rev Neurol., 6, 39, 10.1038/nrneurol.2009.197
Warburg, 1924, Der Tumoren de Stoffwechsel do den de Ueber, Biochem Z, 152, 319
Tennant, 2010, Targeting metabolic transformation for cancer therapy, Nature Rev Cancer, 10, 267, 10.1038/nrc2817
Saiati, 2001, Dietary regulation of expression of glucose-6-phosphate dehydrogenase, Annu Rev Nutr, 21, 121, 10.1146/annurev.nutr.21.1.121
Kim, 2006, HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia, Cell Metab, 3, 177, 10.1016/j.cmet.2006.02.002
Dang, 1999, Oncogenic alteration of metabolism, Trends Biochem Sci, 24, 68, 10.1016/S0968-0004(98)01344-9
Fantin, 2006, Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance, Cancer Cell, 9, 425, 10.1016/j.ccr.2006.04.023
Le, 2010, Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression, Proc Natl Acad Sci USA, 107, 2037, 10.1073/pnas.0914433107
Jones, 2009, Tumor suppressors and cell metabolism: a recipe for cancer growth, Genes Dev, 23, 537, 10.1101/gad.1756509
McFate, 2008, Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells, J Biol Chem, 283, 22700, 10.1074/jbc.M801765200
Sun, 2009, Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo, Breast Cancer Res Treat, 120, 253, 10.1007/s10549-009-0435-9
Gatenby, 2006, Acid-mediated tumor invasion: a multidisciplinary study, Cancer Res, 66, 5216, 10.1158/0008-5472.CAN-05-4193
Mazurek, 2005, Pyruvate kinase type M2 and its role in tumor growth and spreading, Semin Cancer Biol, 15, 300, 10.1016/j.semcancer.2005.04.009
Christofk, 2008, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, Nature, 452, 230, 10.1038/nature06734
Mazurek, 2002, Pyruvate kinase type M2: a crossroad in the tumor metabolome, Br J Nutr, 87, S23, 10.1079/BJN2001454
Christofk, 2008, Pyruvate kinase M2 is a phosphotyrosine-binding protein, Nature, 452, 181, 10.1038/nature06667
Eigenbrodt, 1992, Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells, Crit Rev Oncog., 3, 1
Deprez, 1997, Phosphorylation and activation of heart 6-phosphofructo-2-kinase bt protein kinase B and other protein kinases of the insulin signaling cascades, J Biol Chem, 272, 17269, 10.1074/jbc.272.28.17269
Clem, 2008, Small-molecule inhibition of 6-phosphofructo2-kinase activity suppresses glycolytic flux and tumor growth, Mol Cancer Ther, 7, 110, 10.1158/1535-7163.MCT-07-0482
Mathupala, 2006, Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria, Oncogene, 25, 4777, 10.1038/sj.onc.1209603
Colombini, 2004, VDAC: the channel at the interface between mitochondria and the cytosol, Mol Cell Biochem, 256-7, 107, 10.1023/B:MCBI.0000009862.17396.8d
Oudard, 2003, Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme, J Neurooncol, 63, 81, 10.1023/A:1023756707900
Cao, 2008, Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor, Clin Cancer Res, 14, 1831, 10.1158/1078-0432.CCR-07-1607
Ko, 2004, Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP, Biochem Biophys Res Commun, 324, 269, 10.1016/j.bbrc.2004.09.047
DeBerardinis, 2008, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation, Cell Metab, 7, 11, 10.1016/j.cmet.2007.10.002
Hardie, 2007, AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy, Nature Rev Mol Cell Biol, 8, 774, 10.1038/nrm2249
DeBerardinis, 2007, Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis, Proc Natl Acad Sci USA, 104, 19345, 10.1073/pnas.0709747104
DeBerardinis, 2009, Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer, Oncogene, 29, 313, 10.1038/onc.2009.358
Samid, 1994, Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria, Cancer Res, 54, 891
Rosenfeld, 1981, Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase, Cancer Res, 41, 1324
Hatzivassiliou, 2005, ATP citrate lyase inhibition can suppress tumor cell growth, Cancer Cell, 8, 311, 10.1016/j.ccr.2005.09.008
Li, 2001, Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53, Cancer Res, 61, 1493
Mera, 2009, C75 is converted to C75-CoA in the hypothalamus, where it inhibits carnitine palmitoyltransferase I and decreases food intake and body weight, Biochem Pharmacol, 77, 1084, 10.1016/j.bcp.2008.11.020
Gottlieb, 2005, Mitochondrial tumor suppressors: a genetic and biochemical update, Nature Rev Cancer, 5, 857, 10.1038/nrc1737
Ewald, 2008, Nucleotide analog: molecular mechanisms signaling cell death, Oncogene, 27, 6522, 10.1038/onc.2008.316
Coy, 2005, Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer, Clin Lab, 51, 257
Xu, 2009, Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells, Int J Cancer, 124, 1330, 10.1002/ijc.24078
Duarte, 2007, Global reconstruction of the human metabolic network based on genomic and bibliomic data, Proc Natl Acad Sci USA, 104, 1777, 10.1073/pnas.0610772104
Uno, 2011, IDH1 mutations in a Brazilian series of glioblastoma, Clinics, 66, 163, 10.1590/S1807-59322011000100028
Bleeker, 2009, IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors, Hum Mutat, 30, 7, 10.1002/humu.20937
Geisbretcht, 1999, The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase, J Biol Chem, 274, 30527, 10.1074/jbc.274.43.30527
Yoshihara, 2001, Localization of cytosolic NADP-dependent isocitrate dehydrogenase in the peroxisomes of rat liver cells: biochemical and immunocytochemical studies, J Histochem Cytochem, 49, 1123, 10.1177/002215540104900906
Winkler, 1986, Multiple NADPH-producing pathways control glutathione (GSH) content in retina, Exp Eye Res, 4, 829, 10.1016/S0014-4835(86)80013-6
Haselbeck, 1993, Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenase, J Biol Chem, 268, 12116, 10.1016/S0021-9258(19)50315-5
Reitman, 2010, Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroad of cellular metabolism, J Natl Cancer Inst, 102, 932, 10.1093/jnci/djq187
Thompson, 2009, Metabolic enzymes as oncogenes or tumor suppressors, N Engl J Med, 360, 813, 10.1056/NEJMe0810213
Bleeker, 2010, The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma, Acta Neuropatholol, 119, 487, 10.1007/s00401-010-0645-6
Zhao, 2009, Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha, Science, 324, 261, 10.1126/science.1170944
Fu, 2010, Glioma-derived mutations in IDH: from mechanism to potential therapy, Biochem Biophys Res Commun, 397, 127, 10.1016/j.bbrc.2010.05.115
Yu, 2006, Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology, Proc Natl Acad Sci USA, 103, 2653, 10.1073/pnas.0511154103
Lian, 2011, The importance of mitochondria in the tumourigenic phenotype: gliomas as the paradigm (review), Int J Mol Med, 27, 159
Lee, 2009, Mitochondrial DNA instability and metabolic shift in human cancers, Int J Mol Sci, 10, 674, 10.3390/ijms10020674
Ordys, 2010, The role of mitochondria in glioma pathophysiology, Mol Neurobiol, 42, 64, 10.1007/s12035-010-8133-5
Correia, 2011, Mitochondrial DNA depletion and its correlation with TFAM, TFB1M, TFB2M and POLG in human diffusely infiltrating astrocytomas, Mitochondrion, 11, 48, 10.1016/j.mito.2010.07.001
Santandreu, 2008, Differences in mitochondrial function and antioxidant systems between regions of human glioma, Cel Physiol Biochem, 22, 757, 10.1159/000185559
Gatenby, 2004, Why do cancers have high aerobic glycolysis, Nature Rev Cancer, 4, 891, 10.1038/nrc1478
Xu, 2005, Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia, Cancer Res, 65, 613, 10.1158/0008-5472.613.65.2
Maschek, 2004, 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo, Cancer Res, 64, 31, 10.1158/0008-5472.CAN-03-3294
Papaldo, 2003, Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide, J Clin Oncol, 21, 3462, 10.1200/JCO.2003.03.034
De Lena, 2001, Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer, A phase II study. Eur J Cancer, 37, 364, 10.1016/S0959-8049(00)00400-7
Di Cosimo, 2003, Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors, Drugs Today (Barc), 39, 157, 10.1358/dot.2003.39.3.799451
Kourelis
Jalving, 2010, Metformin: taking away the candy for cancer, Eur J Cancer, 46, 2369, 10.1016/j.ejca.2010.06.012
Evans, 2005, Metformin and reduced risk of cancer in diabetic patients, BMJ, 330, 1304, 10.1136/bmj.38415.708634.F7
Seyfried, 2008, Targeting energy metabolism in brain cancer with calorically restricted ketogenic diets, Epilepsia, 49, 114, 10.1111/j.1528-1167.2008.01853.x
Seyfried, 2009, Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet, J Cancer Res Ther., 5, S7, 10.4103/0973-1482.55134
Smolkova
Scrideli, 2008, Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR, J Neurooncol, 88, 281, 10.1007/s11060-008-9579-4
Marie, 2008, Waves of gene regulation suppress and then restore oxidative phosphorylation, Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer, 122, 807
Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809
Belda-Iniesta, 2008, Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach, Clin Transl Oncol, 10, 73, 10.1007/s12094-008-0159-z
Gallia, 2006, PIK3CA gene mutations in pediatric and adult glioblastoma multiforme, Mol Cancer Res, 4, 709, 10.1158/1541-7786.MCR-06-0172
Scrideli, 2007, Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas, J Neurooncol, 83, 233, 10.1007/s11060-007-9328-0
Barthel, 1999, Regulation of GLUT1 gene transcription by the serine/threonine kinase akt1, J Biol Chem, 274, 20281, 10.1074/jbc.274.29.20281
Pedersen, 2007, Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancer's most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen, J Bioenerg Biomembr, 39, 211, 10.1007/s10863-007-9094-x
Buzzai, 2005, The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation, Oncogene, 16, 4165, 10.1038/sj.onc.1208622
Engelman, 2008, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nature Med, 14, 1351, 10.1038/nm.1890
Bem-Haim, 2009, 18F-FDG PET and PET/CT in the evaluation of cancer treatment response, J Nucl Med, 50, 88, 10.2967/jnumed.108.054205
Elstrom, 2004, Akt stimulates aerobic glycolysis in cancer cells, Cancer Res, 64, 3892, 10.1158/0008-5472.CAN-03-2904
Gleadle, 1998, Hypoxia and the regulation of gene expression, Mol Med Today, 4, 122, 10.1016/S1357-4310(97)01198-2
Semenza, 1994, Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1, J Biol Chem, 269, 23757, 10.1016/S0021-9258(17)31580-6
Yeung, 2008, Roles of p53, MYC and HIF-1 in regulating glycolysis – the seventh hallmark of cancer, Cell Mol Life Sci, 65, 3981, 10.1007/s00018-008-8224-x
Kaelin, 2008, The von Hippel–Lindau suppressor protein: O2 sensing and cancer, Nature Rev Cancer, 8, 865, 10.1038/nrc2502
Semenza, 1996, Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1, J Biol Chem, 271, 32529, 10.1074/jbc.271.51.32529
Minchenko, 2002, Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene, Its possible role in the Warburg effect. J Biol Chem, 277, 6183
Fukasawa, 2004, Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene, J Biochem, 136, 273, 10.1093/jb/mvh137
Kress, 1998, Expression of hypoxia-inducible genes in tumor cells, J Cancer Res Clin Oncol, 124, 315, 10.1007/s004320050175
Kim, 2006, Cancer's molecular sweet tooth and the Warburg effect, Cancer Res, 66, 8927, 10.1158/0008-5472.CAN-06-1501
Stubbs, 2010, The altered metabolism of tumors: HIF-1 and its role in the Warburg effect, Adv Enzyme Regul, 50, 44, 10.1016/j.advenzreg.2009.10.027
Gao, 2009, C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism, Nature, 458, 762, 10.1038/nature07823
Yuneva, 2007, Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells, J Cell Biol, 178, 93, 10.1083/jcb.200703099
Wise, 2008, Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction, Proc Natl Acad Sci USA, 105, 18782, 10.1073/pnas.0810199105
Morrish, 2009, c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry, Oncogene, 28, 2458, 10.1038/onc.2009.112
Prives, 1999, The p53 pathway, J Pathol, 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3
Sidransky, 1996, Clinical implications of the p53 gene, Annu Rev Med, 47, 285, 10.1146/annurev.med.47.1.285
Hupp, 1992, Regulation of the specific DNA binding function of p53, Cell, 71, 875, 10.1016/0092-8674(92)90562-Q
Li, 1969, Soft-tissue sarcomas, breast cancer, and other neoplasms, A familial syndrome? Ann Intern Med, 71, 747, 10.7326/0003-4819-71-4-747
Malkin, 1990, Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms, Science, 250, 1233, 10.1126/science.1978757
Newcomb, 1993, A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme, Brain Pathol, 3, 229, 10.1111/j.1750-3639.1993.tb00749.x
Uno, 2005, Detection of somatic TP53 splice site mutations in diffuse astrocytomas, Cancer Lett, 224, 321, 10.1016/j.canlet.2004.10.022
Ohgaki, 2007, Genetic pathways to primary and secondary glioblastoma, Am J Pathol, 170, 1445, 10.2353/ajpath.2007.070011
Schwartzenberg-Bar-Yoseph, 2004, The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression, Cancer Res, 64, 2627, 10.1158/0008-5472.CAN-03-0846
Kawauchi, 2008, p53 regulates glucose metabolism though an IKK-NF-kappaB pathway and inhibits cell transformation, Nature Cell Biol, 10, 611, 10.1038/ncb1724
Kondoh, 2005, Glycolytic enzymes can modulate cellular lifespan, Cancer Res, 65, 177, 10.1158/0008-5472.177.65.1
Li, 2009, Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator), J Biol Chem, 284, 1748, 10.1074/jbc.M807821200
Mathupala, 1997, Glucose catabolism in cancer cells, The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem, 272, 22776
Vousden, 2009, Functions of p53 in metabolism and invasion, Biochem Soc Trans, 37, 511, 10.1042/BST0370511
Gottlieb, 2010, p53 regulation of metabolic pathways, Cold Spring Harb Perspect Biol, 2, a001040, 10.1101/cshperspect.a001040
Okamura, 1999, Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system, Oncology Res, 11, 281
Bourdon, 2007, Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion, Nature Genet, 39, 776, 10.1038/ng2040
Zhou, 2003, Mitochondrial impairment in p53-deficient human cancer cells, Mutagenesis, 18, 287, 10.1093/mutage/18.3.287
Ma, 2007, A pivotal role for p53: balancing aerobic respiration and glycolysis, J Bioenerg Biomembr, 39, 243, 10.1007/s10863-007-9083-0
Kulawiec, 2009, p53 regulates mtDNA copy number and mitocheckpoint pathway, J Carcinogenesis, 8, 8, 10.4103/1477-3163.50893
Lebedeva, 2009, Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis, Biochim Biophys Acta, 1787, 328, 10.1016/j.bbabio.2009.01.004
Herrero-Mendez, 2009, The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1, Nature Cell Biol, 11, 747, 10.1038/ncb1881
Phillips, 2006, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression and resemble stages in neurogenesis, Cancer Cell, 9, 157, 10.1016/j.ccr.2006.02.019
Bem-Porath, 2008, An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors, Nature Genet, 40, 499, 10.1038/ng.127